INTERPHEX and PDA Announce Sponsorship Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

INTERPHEX and PDA Announce Sponsorship Agreement


International Pharmaceutical Expo (INTERPHEX), an annual trade event dedicated to the pharmaceutical and biopharmaceutical industry, and the Parenteral Drug Association (PDA) announced a three-year sponsorship agreement, which aligns the objectives of both organizations to service key needs of the global pharmaceutical and biopharmaceutical industry by driving innovation and advancement, the organizations report.

INTERPHEX brings together more than 12,000 industry professionals in pharmaceutical and biopharmaceutical manufacturing to learn, network, and source from the latest technology, equipment, education, and services. PDA is a global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical industry. Its mission is to develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of its more than 9,500 global members.

“Our Sponsorship of INTERPHEX reflects our support of the continued enhancement of industry learning and improvement, areas we find present at INTERPHEX,” stated Richard Johnson, president and CEO of PDA. “Non-profits and corporate entities can work together to leverage best practices, in real-time, to the benefit of our industry. Our collaboration with INTERPHEX is one example of this effort and we are pleased to move forward in this shared endeavor.”

PDA will be directly involved in developing the INTERPHEX conference programming, identifying speakers from industry and regulatory agencies, and developing a PDA sponsored cGMP Track. PDA members will have educational and networking opportunities including an exclusive Association Membership Lounge.

“A long-term Sponsorship with PDA, both on national and global levels, aligns us with thought leaders across the globe,” stated Bob Stewart, vice president of INTERPHEX. “By fostering alliances with successful non-profit organizations like PDA, we acknowledge our investment in the future of the biopharmaceutical industry, and ultimately deliver unrivaled opportunities for knowledge, interaction, and professional growth.”

INTERPHEX will be held March 18-20, 2014 at the Jacobs Javits Center in New York City.

Source: INTERPHEX and the Parenteral Drug Association (PDA)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here